Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkermes plc's (the "Company") expectations with respect to its current and future financial, commercial and operating performance, business plans or prospects, including its expected revenue and profitability. The Com ...

Alkermes (ALKS) came out with quarterly earnings of $1.04 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.48 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 28.40%. A quarter ago, it was expected that this drugmaker would post earnings of $0.78 per share when it actually produced earnings of $0.73, delivering a surprise of -6.41%.Over the last four quarters, the company has s ...

Corporate Presentation at J.P. Morgan Healthcare Conference - Alkermes plc will present its corporate presentation at the J.P. Morgan Healthcare Conference on January 15, 2025, including expectations for cash and investments for the year ended December 31, 2024 [5] - The corporate presentation is furnished as Exhibit 99.1 and incorporated by reference in Item 7.01 [6] - Alkermes plc's corporate presentation is listed as Exhibit 99.1 in the Exhibit Index [9] Form 8-K Filing Information - The information in the Form 8-K, including Items 2.02 and 7.01, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 [7]

Financial Performance - Total revenues for 2024 were reported at $1.56 billion, with proprietary product net sales increasing approximately 18% year-over-year [1][3] - GAAP net income from continuing operations was $372 million, translating to diluted GAAP earnings per share of $2.20 for 2024 [1][3] - The company generated over $1 billion in revenue from its proprietary commercial product portfolio and delivered EBITDA from continuing operations of approximately $452 million [2][3] Product Performance - Proprietary net sales for the fourth quarter of 2024 were $307.7 million, compared to $242.0 million in the same quarter of 2023, marking a significant increase [3][12] - Key products included VIVITROL® with revenues of $134.1 million (up 31% year-over-year), ARISTADA® with $96.6 million (up 16%), and LYBALVI® with $77.0 million (up 37%) [3][12] Operational Developments - The company completed the sale of its manufacturing business in Ireland and ended 2024 debt-free with approximately $825 million in cash and investments [2][13] - Ongoing Phase 2 studies for ALKS 2680 in narcolepsy are expected to yield data in the second half of 2025, with plans to initiate additional studies in idiopathic hypersomnia [2][1] Financial Expectations for 2025 - The company anticipates total revenues between $1.34 billion and $1.43 billion for 2025, with specific net sales expectations for VIVITROL, ARISTADA, and LYBALVI [15] - Projected GAAP net income for 2025 is estimated to be between $175 million and $205 million, with EBITDA expected to range from $215 million to $245 million [15][34]

Core Viewpoint - Alkermes plc will host a conference call and webcast on February 12, 2025, to discuss its fourth quarter and year-end 2024 financial results, along with financial expectations for 2025 and company updates [1]. Company Overview - Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines in neuroscience, with a portfolio addressing alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder [3]. - The company has a pipeline of clinical and preclinical candidates targeting neurological disorders, including narcolepsy and idiopathic hypersomnia [3]. - Alkermes is headquartered in Ireland, with additional offices and facilities in Massachusetts and Ohio [3].

Group 1 - Alkermes plc will participate in two upcoming investor conferences: the 7th Annual Evercore ISI HealthCONx Conference on December 3, 2024, and the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024 [1] - The live webcasts of the conferences will be accessible under the Investors tab on Alkermes' website and will be archived for 14 days [1] Group 2 - Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines in neuroscience [2] - The company has a portfolio of proprietary commercial products targeting alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder [2] - Alkermes is headquartered in Ireland, with additional offices in Massachusetts and a manufacturing facility in Ohio [2]

Group 1 - Alkermes plc will participate in two upcoming investor conferences: Stifel Healthcare Conference on November 18, 2024, at 8:35 a.m. ET and Jefferies London Healthcare Conference on November 19, 2024, at 8:00 a.m. ET [1] - Live webcasts of the conferences will be available under the Investors tab on Alkermes' website and will be archived for 14 days [1] Group 2 - Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines in neuroscience [2] - The company has a portfolio of proprietary commercial products targeting alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder [2] - Alkermes has a pipeline of clinical and preclinical candidates for neurological disorders, including narcolepsy and idiopathic hypersomnia [2] - The company is headquartered in Ireland, with additional offices in Massachusetts and a manufacturing facility in Ohio [2]

Alkermes plc (ALKS) reported adjusted earnings from continuing operations of 73 cents per share for thirdquarter 2024, which missed the Zacks Consensus Estimate of 78 cents. The company had reported adjusted earnings of 87 cents per share in the year-ago quarter. ALKS' total revenues of $378.1 million declined 0.7% from the year-ago quarter's level owing to lower manufacturing and royalty revenues. The top line, also, missed the Zacks Consensus Estimate of $386 million. Shares of Alkermes were down 3.6% on ...

Alkermes plc (NASDAQ:ALKS) Q3 2024 Earnings Conference Call October 24, 2024 8:00 AM ET Company Participants Sandra Coombs - Senior Vice President of Investor Relations and Corporate Affairs Richard Pops - CEO Todd Nichols - Chief Commercial Officer Blair Jackson - Chief Operating Officer. Conference Call Participants Joseph Thome - TD Cowen Umer Raffat - Evercore Paul Matteis - Stifel Charles Duncan - Cantor Fitzgerald David Amsellem - Piper Sandler Joel Beatty - Baird Uy Ear - Mizuho Securities Jessica Fy ...

Alkermes (ALKS) reported $378.14 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 0.7%. EPS of $0.73 for the same period compares to $0.64 a year ago.The reported revenue represents a surprise of -2.06% over the Zacks Consensus Estimate of $386.09 million. With the consensus EPS estimate being $0.78, the EPS surprise was -6.41%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determin ...